Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23166181 | 0.77 | BRD4 (0.49) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL29710178 | 0.77 | BRD4 (0.49) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL3349243 | 0.75 | BRD4 (0.45) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL31207459 | 0.72 | PRKCI (0.46) | — | |
| SCHEMBL30296446 | 0.71 | BMPR1B (0.39) | BRD4CREBBP | |
| SCHEMBL30296424 | 0.70 | HRH3 (0.45) | — | |
| SCHEMBL30296558 | 0.70 | CSNK2A1 (0.44) | ADORA2AADORA1 | |
| SCHEMBL1571625 | 0.70 | BRD4 (0.50) | BRD4ADORA2AADORA1ADORA2BCREBBP | |
| SCHEMBL26456968 | 0.70 | CSNK2A1 (0.44) | ADORA2AADORA1 | |
| SCHEMBL1912411 | 0.69 | NSD2 (0.46) | BRD4ADORA2AADORA1ADORA2BCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |